NCT05080816

Brief Summary

The study investigates effects related to muscle protein metabolism at provision of Parenteral or enteral nutrition

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2017

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 18, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 18, 2018

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

June 10, 2021

Completed
4 months until next milestone

First Posted

Study publicly available on registry

October 18, 2021

Completed
Last Updated

October 18, 2021

Status Verified

October 1, 2021

Enrollment Period

1.7 years

First QC Date

June 10, 2021

Last Update Submit

October 4, 2021

Conditions

Keywords

Skeletal muscle

Outcome Measures

Primary Outcomes (1)

  • Muscle protein metabolism

    Alterations in skeletal muscle gene expression quantified by microarray

    ~12-14 hours.

Study Arms (3)

Parenteral nutrition

ACTIVE COMPARATOR

Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.

Dietary Supplement: Parenteral nutrition (PN)

Enteral nutrition

ACTIVE COMPARATOR

Oral nutrition drink. 2 \* 200 ml on the night before operation. 1\* 200 ml on the morning of operation day.

Dietary Supplement: Enteral nutrition

control

PLACEBO COMPARATOR

Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN

Other: Control

Interventions

Parenteral nutrition (PN)DIETARY_SUPPLEMENT

Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.

Also known as: Total parenteral nutrition (TPN)
Parenteral nutrition
Enteral nutritionDIETARY_SUPPLEMENT

Oral nutrition drink. 2 \* 200 ml on the night before operation. 1\* 200 ml on the morning of operation day.

Also known as: nutrition drink
Enteral nutrition
ControlOTHER

Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN

control

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Major gastrointestinal surgery.
  • Assumed need of post-operative nutrition support.

You may not qualify if:

  • Insulin dependent diabetes.
  • Steroid medication.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sahlgrenska University Hospital

Gothenburg, Region Västra Götaland, 41345, Sweden

Location

Related Publications (1)

  • Iresjo BM, Smedh U, Engstrom C, Persson J, Martensson C, Lundholm K. A randomized translational study on protein- and glucose metabolism in skeletal muscles evaluated by gene-ontology, following preoperative oral carbohydrate loading compared to overnight peripheral parenteral nutrition (PPN) before major cancer surgery. J Transl Med. 2024 Jul 22;22(1):675. doi: 10.1186/s12967-024-05484-1.

MeSH Terms

Conditions

Muscular Atrophy

Interventions

Parenteral NutritionParenteral Nutrition, TotalEnteral Nutrition

Condition Hierarchy (Ancestors)

Neuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Feeding MethodsTherapeuticsNutritional SupportNutrition Therapy

Study Officials

  • Britt-Marie Iresjö, Ph.D

    Göteborg University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Persons responsible for genomic/transcriptomic/proteomics analyses are blinded. All samples are coded.
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 10, 2021

First Posted

October 18, 2021

Study Start

February 1, 2017

Primary Completion

October 18, 2018

Study Completion

October 18, 2018

Last Updated

October 18, 2021

Record last verified: 2021-10

Locations